- Conditions
- Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more